Emerging roles of DYRK2 in cancer

Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133

(2020) Yahu A. Liu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Updating dual-specificity tyrosine-phosphorylation-regulated kinase 2 (DYRK2): molecular basis, functions and role in diseases

(2020) Alejandro Correa-Sáez et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

An exon skipping screen identifies antitumor drugs that are potent modulators of pre-mRNA splicing, suggesting new therapeutic applications

(2020) Yihui Shi et al.   PLoS One

Proline Hydroxylation Primes Protein Kinases for Autophosphorylation and Activation

(2020) Sang Bae Lee et al.   MOLECULAR CELL

Use of peripheral blood transcriptomic biomarkers to distinguish high‑grade cervical squamous intraepithelial lesions from low‑grade lesions

(2020) Cunhua Zou et al.   Oncology Letters

Multi-layered proteomic analyses decode compositional and functional effects of cancer mutations on kinase complexes

(2020) Martin Mehnert et al.   Nature Communications

The novel ciliogenesis regulator DYRK2 governs Hedgehog signaling during mouse embryogenesis

(2020) Saishu Yoshida et al.   eLife

The Human Novel Gene LNC-HC Inhibits Hepatocellular Carcinoma Cell Proliferation by Sequestering hsa-miR-183-5p

(2020) Xi Lan et al.   Molecular Therapy-Nucleic Acids

The DYRK Family of Kinases in Cancer: Molecular Functions and Therapeutic Opportunities

(2020) Jacopo Boni et al.   Cancers

DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis

(2020) Amina Jamal Laham et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Mapping the Human Kinome in Response to DNA Damage

(2019) Michel Owusu et al.   Cell Reports

TERT gene: its function and dysregulation in cancer

(2019) Andrew J Colebatch et al.   JOURNAL OF CLINICAL PATHOLOGY

Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease

(2019) Benoît Melchior et al.   AGING CELL

Forced expression of DYRK2 exerts anti-tumor effects via apoptotic induction in liver cancer

(2019) Shiho Yokoyama-Mashima et al.   CANCER LETTERS

p38 Stabilizes Snail by Suppressing DYRK2-Mediated Phosphorylation that is Required for GSK3β-βTrCP-Induced Snail Degradation

(2019) Ki-Jun Ryu et al.   CANCER RESEARCH

Chronic Dyrk1 Inhibition Delays the Onset of AD-Like Pathology in 3xTg-AD Mice

(2019) R. Velazquez et al.   MOLECULAR NEUROBIOLOGY

Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas

(2019) Lawrence A. Donehower et al.   Cell Reports

KLF4 Represses DYRK2 Inhibition of Self-renewal and Survival Through c-Myc and p53 in Leukemia Stem/Progenitor Cells

(2019) Chun Shik Park et al.   BLOOD

Multiple functions of DYRK2 in cancer and tissue development

(2019) Saishu Yoshida et al.   FEBS LETTERS

Cell Fate Regulation upon DNA Damage: p53 Serine 46 Kinases Pave the Cell Death Road

(2019) Magdalena C. Liebl et al.   BIOESSAYS

Phosphorylation-dependent regulation of the NOTCH1 intracellular domain by dual-specificity tyrosine-regulated kinase 2

(2019) Rosario Morrugares et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

DNA Methylation of Dual-Specificity Tyrosine-Regulated Kinase 2 (DYRK2) Promoter Regulates Proliferation of Human Colorectal Cancer

(2019) Tomotaka Kumamoto et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression

(2019) Sourav Banerjee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Deep multiomics profiling of brain tumors identifies signaling networks downstream of cancer driver genes

(2019) Hong Wang et al.   Nature Communications

Downregulation of dual-specificity tyrosine-regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin-dependent kinase 14 expression in breast cancer

(2018) Yoshimi Imawari et al.   CANCER SCIENCE

STAT3, stem cells, cancer stem cells and p63

(2018) Michaela Galoczova et al.   CELLULAR & MOLECULAR BIOLOGY LETTERS

HIV-1 Vpr hijacks EDD-DYRK2-DDB1DCAF1to disrupt centrosome homeostasis

(2018) Delowar Hossain et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2

(2018) Sourav Banerjee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives

(2018) Fernanda Neumann et al.   Scientific Reports

Clinical relevance of cytoskeleton associated proteins for ovarian cancer

(2018) Johanna Schiewek et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Small Molecule Inhibitors of HSF1-Activated Pathways as Potential Next-Generation Anticancer Therapeutics

(2018) Chiranjeev Sharma et al.   MOLECULES

Regulation of the mammalian heat shock factor 1

(2017) Sharadha Dayalan Naidu et al.   FEBS Journal

The Essential Medicinal Chemistry of Curcumin

(2017) Kathryn M. Nelson et al.   JOURNAL OF MEDICINAL CHEMISTRY

Marine-Derived 2-Aminoimidazolone Alkaloids. Leucettamine B-Related Polyandrocarpamines Inhibit Mammalian and Protozoan DYRK & CLK Kinases

(2017) Nadège Loaëc et al.   Marine Drugs

Regulation of Glioma Cells Migration by DYRK2

(2017) Yifen Shen et al.   NEUROCHEMICAL RESEARCH

Decrease of miR-622 expression suppresses migration and invasion by targeting regulation of DYRK2 in colorectal cancer cells

(2017) Yong Wang et al.   OncoTargets and Therapy

Inhibition of DYRK1A disrupts neural lineage specificationin human pluripotent stem cells

(2017) Stephanie F Bellmaine et al.   eLife

A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition

(2016) Hyeongki Kim et al.   Disease Models & Mechanisms

An Unusual Binding Model of the Methyl 9-Anilinothiazolo[5,4-f] quinazoline-2-carbimidates (EHT 1610 and EHT 5372) Confers High Selectivity for Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases

(2016) Apirat Chaikuad et al.   JOURNAL OF MEDICINAL CHEMISTRY

Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer

(2016) R Mimoto et al.   ONCOGENE

Downregulation of the proapoptotic protein MOAP-1 by the UBR5 ubiquitin ligase and its role in ovarian cancer resistance to cisplatin

(2016) K Matsuura et al.   ONCOGENE

Downregulated DYRK2 expression is associated with poor prognosis and Oxaliplatin resistance in hepatocellular carcinoma

(2016) Xiubing Zhang et al.   PATHOLOGY RESEARCH AND PRACTICE

Selective inhibition of the kinase DYRK1A by targeting its folding process

(2016) Isao Kii et al.   Nature Communications

miR-129-3p controls centrosome number in metastatic prostate cancer cells by repressing CP110

(2016) Irene V. Bijnsdorp et al.   Oncotarget

Low Expression of DYRK2 (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2) Correlates with Poor Prognosis in Colorectal Cancer

(2016) Haiyan Yan et al.   PLoS One

Phosphorylation-dependent regulation of Notch1 signaling: the fulcrum of Notch1 signaling

(2015) Hye-Jin Lee et al.   BMB Reports

CDK2 Inhibition Causes Anaphase Catastrophe in Lung Cancer through the Centrosomal Protein CP110

(2015) S. Hu et al.   CANCER RESEARCH

MEK Guards Proteome Stability and Inhibits Tumor-Suppressive Amyloidogenesis via HSF1

(2015) Zijian Tang et al.   CELL

Causes and consequences of protein folding stress in aneuploid cells

(2015) Neysan Donnelly et al.   CELL CYCLE

Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma

(2015) Yuchan Wang et al.   INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

10-Iodo-11H-indolo[3,2-c]quinoline-6-carboxylic Acids Are Selective Inhibitors of DYRK1A

(2015) Hannes Falke et al.   JOURNAL OF MEDICINAL CHEMISTRY

A novel DYRK1A (Dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologiesin vitro

(2015) Séverine Coutadeur et al.   JOURNAL OF NEUROCHEMISTRY

When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response

(2015) S. P. Shah et al.   MOLECULAR CANCER RESEARCH

Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis

(2015) Xing Guo et al.   NATURE CELL BIOLOGY

The Expression of the Ubiquitin Ligase SIAH2 (Seven In Absentia Homolog 2) Is Increased in Human Lung Cancer

(2015) Paula Moreno et al.   PLoS One

DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma

(2015) Noriko Yamaguchi et al.   TUMOR BIOLOGY

Aneuploidy generates proteotoxic stress and DNA damage concurrently with p53-mediated post-mitotic apoptosis in SAC-impaired cells

(2015) Akihiro Ohashi et al.   Nature Communications

Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways

(2015) Xinyan Wu et al.   Oncotarget

Identification of a DYRK1A Inhibitor that Induces Degradation of the Target Kinase using Co-chaperone CDC37 fused with Luciferase nanoKAZ

(2015) Rie Sonamoto et al.   Scientific Reports

DYRK2 Negatively Regulates Type I Interferon Induction by Promoting TBK1 Degradation via Ser527 Phosphorylation

(2015) Tai An et al.   PLoS Pathogens

Selectivity Profiling and Biological Activity of Novel β-Carbolines as Potent and Selective DYRK1 Kinase Inhibitors

(2015) Katharina Rüben et al.   PLoS One

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

(2014) Patricia A.J. Muller et al.   CANCER CELL

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

(2014) Lawrence M. Gelbert et al.   INVESTIGATIONAL NEW DRUGS

Hypoxia regulates Hippo signalling through the SIAH2 ubiquitin E3 ligase

(2014) Biao Ma et al.   NATURE CELL BIOLOGY

Kinase Drug Discovery – What’s Next in the Field?

(2013) Philip Cohen et al.   ACS Chemical Biology

Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the LKB1-tumour-suppressor-activated NUAK kinases

(2013) Sourav Banerjee et al.   BIOCHEMICAL JOURNAL

Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases

(2013) Giorgio Cozza et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

The E3 Ubiquitin Ligase Siah2 Contributes to Castration-Resistant Prostate Cancer by Regulation of Androgen Receptor Transcriptional Activity

(2013) Jianfei Qi et al.   CANCER CELL

DYRK2 controls the epithelial–mesenchymal transition in breast cancer by degrading Snail

(2013) Rei Mimoto et al.   CANCER LETTERS

Dual Specificity Kinase DYRK3 Couples Stress Granule Condensation/Dissolution to mTORC1 Signaling

(2013) Frank Wippich et al.   CELL

Dyrk2-associated EDD-DDB1-VprBP E3 Ligase Inhibits Telomerase by TERT Degradation

(2013) Hae-Yun Jung et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

HIV-1 Vpr Protein Inhibits Telomerase Activity via the EDD-DDB1-VPRBP E3 Ligase Complex

(2013) Xin Wang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Mouse models for lung cancer

(2013) Min-chul Kwon et al.   Molecular Oncology

Mutational landscape and significance across 12 major cancer types

(2013) Cyriac Kandoth et al.   NATURE

Sporadic Colorectal Cancer Development Shows Rejuvenescence Regarding Epithelial Proliferation and Apoptosis

(2013) Katalin Leiszter et al.   PLoS One

Structures of Down Syndrome Kinases, DYRKs, Reveal Mechanisms of Kinase Activation and Substrate Recognition

(2013) Meera Soundararajan et al.   STRUCTURE

Structure–activity relationship study of beta-carboline derivatives as haspin kinase inhibitors

(2012) Gregory D. Cuny et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

HSF1 Drives a Transcriptional Program Distinct from Heat Shock to Support Highly Malignant Human Cancers

(2012) Marc L. Mendillo et al.   CELL

DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells

(2012) Naoe Taira et al.   JOURNAL OF CLINICAL INVESTIGATION

A Natural Small Molecule Harmine Inhibits Angiogenesis and Suppresses Tumour Growth through Activation of p53 in Endothelial Cells

(2012) Fujun Dai et al.   PLoS One

Mutual regulation between SIAH2 and DYRK2 controls hypoxic and genotoxic signaling pathways

(2012) Moisés Pérez et al.   Journal of Molecular Cell Biology

Novel Inverse Binding Mode of Indirubin Derivatives Yields Improved Selectivity for DYRK Kinases

(2012) Vassilios Myrianthopoulos et al.   ACS Medicinal Chemistry Letters

Leucettines, a Class of Potent Inhibitors of cdc2-Like Kinases and Dual Specificity, Tyrosine Phosphorylation Regulated Kinases Derived from the Marine Sponge Leucettamine B: Modulation of Alternative Pre-RNA Splicing

(2011) Mansour Debdab et al.   JOURNAL OF MEDICINAL CHEMISTRY

Structure–activity relationship study of acridine analogs as haspin and DYRK2 kinase inhibitors

(2010) Gregory D. Cuny et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

CX-4945, an Orally Bioavailable Selective Inhibitor of Protein Kinase CK2, Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor Efficacy

(2010) A. Siddiqui-Jain et al.   CANCER RESEARCH

DYRK family of protein kinases: evolutionary relationships, biochemical properties, and functional roles

(2010) Sergi Aranda et al.   FASEB JOURNAL

Heat-shock transcription factor HSF1 has a critical role in human epidermal growth factor receptor-2-induced cellular transformation and tumorigenesis

(2010) L Meng et al.   ONCOGENE

Correction: Protein Kinase A Binds and Activates Heat Shock Factor 1

(2010) Ayesha Murshid et al.   PLoS One

New Roles for the LKB1-NUAK Pathway in Controlling Myosin Phosphatase Complexes and Cell Adhesion

(2010) A. Zagorska et al.   Science Signaling

Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A

(2010) Yasushi Ogawa et al.   Nature Communications

Getting to First Base in Proteasome Assembly

(2009) Henrike C. Besche et al.   CELL

Role of p53/FAK association and p53Ser46phosphorylation in staurosporine-mediated apoptosis: Wild type versus mutant p53-R175H

(2009) Stephanie Fanucchi et al.   FEBS LETTERS

ATM Augments Nuclear Stabilization of DYRK2 by Inhibiting MDM2 in the Apoptotic Response to DNA Damage

(2009) Naoe Taira et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Expression of dual-specificity tyrosine-(Y)-phosphorylation–regulated kinase 2 (DYRK2) can be a favorable prognostic marker in pulmonary adenocarcinoma

(2009) Shin-ichi Yamashita et al.   JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY

Protein kinase DYRK2 is a scaffold that facilitates assembly of an E3 ligase

(2009) Subbareddy Maddika et al.   NATURE CELL BIOLOGY

The selectivity of inhibitors of protein kinase CK2: an update

(2008) Mario A. Pagano et al.   BIOCHEMICAL JOURNAL

Cdk5-mediated Phosphorylation of c-Myc on Ser-62 Is Essential in Transcriptional Activation of Cyclin B1 by Cyclin G1

(2008) Haeng Ran Seo et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Notch tumor suppressor function

(2008) G P Dotto   ONCOGENE

A quantitative atlas of mitotic phosphorylation

(2008) N. Dephoure et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA